ISPOR SPONSORING SESSION AT DIA 2016 THIS JUNE

Published Apr 5, 2016
ANNOUNCEMENT

SOCIETY’S PRESIDENT-ELECT, LOU GARRISON, LEADING WORKSHOP

Princeton, NJ—April 5, 2016—The International Society for Pharmacoeconomics and Outcomes Research (ISPOR) is attending and contributing to the Drug Information Association (DIA) Annual Meeting being held June 26-30, 2016 in Philadelphia, PA, USA.  ISPOR will be sponsoring a preconference workshop on Sunday, June 26 at DIA 2016. ISPOR President-Elect Lou Garrison, PhD will be one of the instructors for the half-day session entitled, The Evolving Role of Payers in Drug Development: Pricing, Pharmacoeconomics, and Health Technology Assessment. ISPOR is offering this preconference tutorial at this event to provide expanded access to educational resources as part of its mission to promote health economics and outcomes research (HEOR) excellence to improve decision making for health globally. For additional information, please contact Betsy Lane, director, chief marketing and communications officer at BLane@ispor.org or 609-586-4981 x112.

###

Related Stories

Landmark Analysis in Value in Health Uncovers Potential Research Efficiency Gains

Sep 15, 2025

Value in Health, the official journal of ISPOR announced the publication of a landmark scoping review that provides a comprehensive mapping of patient preference studies across key medical domains, revealing the first robust evidence base for advancing meta-analyses and benefit transfer methods in healthcare decision-making.

ISPOR Real-World Evidence Summit 28-30 September 2025 | Tokyo, Japan

Sep 9, 2025

ISPOR announced details for its ISPOR Real-World Evidence Summit 2025: Through The Lens of Asia Pacific. The Summit brings together top experts, decision makers, and industry leaders to explore the latest breakthroughs, share cutting-edge research, and discuss innovative solutions to the region’s most pressing healthcare challenges.

"Most-Favored Nation" Drug Pricing Strategy May Backfire, New Research Warns

Sep 3, 2025

Value in Health, the official journal of ISPOR announced the publication of a new analysis suggesting that the Trump Administration's "Most-Favored Nation" approach to lowering US drug prices by referencing international prices may not achieve its intended goals, based on decades of experience with similar policies in Europe.
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×